RBC Capital Adds 'Speculative Risk' Qualifier to Concordia (CXRX) Rating, PT Cut to $14

September 19, 2016 8:37 AM EDT
Get Alerts CXRX Hot Sheet
Price: $2.38 --0%

Rating Summary:
    0 Buy, 4 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 4
Trade CXRX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

RBC Capital analyst Douglas Miehm added a Speculative Risk qualifier to his Outperform rating on Concordia Healthcare (NASDAQ: CXRX) and lowered his price target to $14.00 (from $25.00).

Miehm commented, "The NHS tabled a bill late last week to further control UK medical costs. While we have highlighted this risk for some time, we note that the impact on AMCo remains relatively unknown, so we have adopted a cautious stance and reduced 2017E revenues by ~$32MM and Adj. EBITDA by ~$26MM. While CXRX appears inexpensive, we have assigned a Speculative Risk qualifier given likely volatility. We also lower our price target to $14 from $25."

For an analyst ratings summary and ratings history on Concordia Healthcare click here. For more ratings news on Concordia Healthcare click here.

Shares of Concordia Healthcare closed at $5.40 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

RBC Capital

Add Your Comment